Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (for ezetimibe) Clear all

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Rosuvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 54
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more

Conditions: Metabolic Syndrome
Interventions: Simvastatin, Vytorin, Placebo, Ezetimibe; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hypercholesterolemia
Interventions: Enlicitide, Ezetimibe, Bempedoic Acid, Placebo for Enlicitide, Placebo for Ezetimibe, Placebo for Bempedoic Acid; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Lincoln, California • Flossmoor, Illinois • Louisville, Kentucky + 4 more

Conditions: Hyperlipidemia
Interventions: Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia

Conditions: Hypercholesterolemia
Interventions: ezetimibe, Placebo; Drug
Lead sponsor: Radiant Research; Other
Eligibility: 21 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Hypercholesterolemia
Interventions: LY3015014, Placebo, Statin, Ezetimibe; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Encino, California • Lancaster, California • Spring Valley, California + 12 more

Conditions: Inflammation
Interventions: Vytorin, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypercholesterolemia
Interventions: ezetimibe, placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Chronic Hepatitis C
Interventions: 20mg ezetimibe, Placebo, 40mg ezetimibe; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions: Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more

Search by objective public record fields.

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

A Study of LY3015014 in Participants With High Cholesterol

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C